Predictive Value of Serum Heat Shock Protein 90α on the Prognosis of Patients with Lung Adenocarcinoma

Abstract

Purpose Heat shock protein 90α (HSP90α) is highly expressed in tumors, and predicts tumor progression. This study analyzed the correlation between the expression level of HSP90α in the serum and the prognosis of patients with lung adenocarcinoma. Patients and methods The medical records of patients with 228 lung adenocarcinoma from September 2015 to December 2021 were analyzed. HSP90α expression in the patients’ serum was detected by ELISA and the cut-off value (93.76 ng/mL) was determined according to the ROC curve, then the patients were divided into high- and low-level groups. The differences in the medical records of the two groups were compared using the X 2 test, and Univariate and multivariate Cox regression analyses showed that serum HSP90α level were independent risk factors for both PFS and OS ( P < 0.05). Results HSP90α was positively correlated with TNM staging ( P < 0.01) by One-way analysis of variance. The results of the correlation analysis and the Kaplan–Meier survival curve showed that the expression levels of HSP90α and CEA of patients were positively correlated (R=0.54, P < 0.001), and patients with high HSP90α and CEA levels had the worst OS ( P < 0.001). Conclusion HSP90α expression is negatively correlated with the prognosis of patients with lung adenocarcinoma and is a potential prognostic marker.

Emerging Biosensing Methods to Monitor Lung Cancer Biomarkers in Biological Samples: A Comprehensive Review

“…Moreover, HSP90α expression was higher in lung cancer patients’ serum in comparison to healthy individuals’ serum, indicating that HSP90 could be employed as a novel biomarker for the diagnosis of lung cancer [ 225 ]. A recent study by Fang et al found that HSP90α expressions were positively correlated with tumor–node–metastasis staging in patients with lung adenocarcinoma and suggested combining HSP90α with carcinoembryonic antigen for more effective prediction of patient prognosis [ 226 ]. The growing evidence that shows a link between HSP expression and lung cancer differentiation and staging suggests that HSPs can be used as a potential biomarker and therapeutic target to treat lung cancer.…”